Sechs Zentren, sechs Städte, eine Mission: Start-ups von der ersten Idee an zu begleiten. Eine Reise durch den deutschen Life Sciences-Kosmos.Deutschland gehört zu den stärksten Life Sciences-Standorten der Welt. Die Biotechnologiebranche sammelte 2025 laut EY Biotech Report Germany 2025, trotz des
Bildnachweis: Life Science Factory.Die Ludwig-Maximilians-Universität München (LMU) und die Life Science Factory München haben eine strategische Partnerschaft geschlossen. Ziel ist es, Forschung, Gründung und unternehmerische Umsetzung im Life-Science-Bereich enger zu verzahnen. Damit wollen beide P
Bildnachweis: Pexels.Der europäische Private-Equity- und Venture-Capital-Investor Andera Partners wird Mitglied der European Life Sciences Coalition (ELSC). Die gemeinsam mit Invest Europe ins Leben gerufene Initiative verfolgt das Ziel, das europäische Venture-Capital-Ökosystem im Bereich Life Scie
Bildnachweis: VC Magazin.Germany conducts world-class research, but faces a critical gap in scale-up capital. While regulatory frameworks are still being debated here, other regions are already creating facts on the ground. At the inaugural ‚Impact Life Sciences Deep Dive‘ hosted by EY and VentureCa
Bildnachweis: Melodia Therapeutics/Jacobian/Azafaros.The Strüngmann Award has entered its decisive phase with the announcement of the three finalists for the 2026 edition. Presented for the third consecutive year, the award honours outstanding entrepreneurs from the DACH life sciences sector who hav
Bildnachweis: PwC Germany; Simplants.PwC Germany’s ‘Scale Program Cloud in Healthcare’ connects investors, corporates, hospitals, and B2B healthtech start-ups to accelerate clinically validated innovation. Simplants, part of the programme, is developing a data-driven platform for medtech procurement
Bildnachweis: NVision.Fresh capital and a strategic pivot: how Ulm-based deeptech company NVision is transforming from a sensing hardware provider into a holistic ‘compute and validate’ platform for the pharmaceutical industry. NVision initially made waves with Polaris, a quantum-enhanced MRI platfo
Bildnachweis: BioM.Die bayerische Biotechnologiebranche hat ihren Wachstumskurs im Jahr 2025 fortgesetzt. Trotz eines herausfordernden internationalen Marktumfelds stieg die Zahl der Unternehmen im Biopharma-Sektor um 1,5 % auf insgesamt 548. Gleichzeitig erreichten die Finanzierungen und Fördermitt
Bildnachweis: Nuclidium.Dr Leila Jaafar-Thiel, CEO of Nuclidium, explains how the company’s copper-based radiotheranostic approach will become a milestone in precision oncology for an improved individual treatment of patients.VC Magazin: In less than twelve months, Nuclidium has raised approximately
Bildnachweis: Dr Philipp Schenk, McKinsey, T-Knife, FGK Clinical Research, Andera Partners, WuxiAppTec/Mikhail Glabets Photography.Modern drug development is an inherently complex under-taking: bringing a new therapy from discovery to market requires highly specialised expertise, cutting-edge infras
Bildnachweis: VC Magazin/brutkasten.Die deutsche Biotech-Branche hat sich 2025 in einem schwierigen Marktumfeld behauptet, kämpft jedoch weiterhin mit strukturellen Herausforderungen bei der Finanzierung. Das geht aus dem „German Biotechnology Report 2026“ der Prüfungs- und Beratungsgesellschaft EY-
The market for Contract Development and Manufacturing Organisations (CDMOs) and Contract Research Organisations (CROs) continues to grow strongly. As biotechnology companies increasingly outsource development as well as clinical and manufacturing processes, the sector remains one of the fastest-grow
Bildnachweis: Noctrix Health.Angelini Ventures, the corporate venture arm of Angelini Industries focused on Biotech and Healthtech investments, has announced the acquisition of its portfolio company Noctrix Health by ResMed (NYSE: RMD), a global provider of sleep health and respiratory care solution
Bildnachweis: Nuclidium.Nuclidium, a clinical-stage radiopharmaceutical company, has announced the successful closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension round, bringing the total Series B financing to CHF 105 million (approximately EUR 115 million). The financi
Bildnachweis: VentureCapital Magazin, Pixabay.Theranostics is on the rise and is becoming an exciting investment opportunity for private equity firms and other investors. In Germany, the Dresden’s Radiopharmaceutical Cluster is setting the tone as a network and innovation hub.For the Dresden-based r
Bildnachweis: Rivermark Medical.Andera Partners has led a 20 million USD Series D financing round in Rivermark Medical, underscoring continued investor confidence in minimally invasive therapies for benign prostatic hyperplasia (BPH). The financing round, which also drew participation from existing
Bildnachweis: Topadur Pharma AG.The mission of the Swiss biopharmaceutical Topadur is not only to dilate blood vessels, but also to cause them to regenerate. Its innovative drugs, partly already in clinical development, have the potential to delay or prevent debilitating diseases and extend healthy
Bildnachweis: Dr. Holger Bengs, BCNP Consultants.Public funding mitigates risks, but it cannot replace equity. Life sciences founders who merely jump from one funding deadline to the next, or who masquerade as tech companies for investors, lose sight of what matters most: the market. In our intervie
Bildnachweis: Foto von ThisisEngineering auf Unsplash.Drug development, medical technology, or digital health: few industries are as capital-intensive as the life sciences. Yet, knowing precisely when to submit which application can drastically reduce burn rates and effectively extend a start-up’s r
Bildnachweis: Swiss Biotech Association.The Swiss Biotech Day 2026 has kicked off in Basel from May 4-5, once again positioning Switzerland at the center of the global biotech dialogue. Over two days more than 3,000 industry leaders, investors and scientists from around the world have gathered to di
Bildnachweis: Swiss Biotech Association.Switzerland’s biotech sector delivered a robust performance in 2025, underlining its resilience in a challenging global environment. According to the Swiss Biotech Report 2026, unveiled at the Swiss Biotech Day 2026 in Basel by the Swiss Biotech Association in
Bildnachweis: Siegfried.DINAMIQS, a Siegfried company (SIX: SFZN), announces that it has received the manufacturing and testing license from Swissmedic for viral vector cGMP production. With this approval, DINAMIQS is now authorized to manufacture and release Advanced Therapeutic Medicinal Products
Bildnachweis: Primogene.Das Leipziger Biotech-Start-up Primogene GmbH hat 4,1 Mio. EUR im Rahmen einer Seedfinanzierung eingesammelt. Das Kapital soll helfen, seine komplexen bioaktiven Moleküle in industriellem Maßstab auf den Markt zu bringen. Mithilfe einer enzymatischen Plattformtechnologie pro
Bildnachweis: mbiomics, MIG Capital.Das Start-up mbiomics, das skalierbare, mikrobiombasierte Therapeutika für schwere und chronische Erkrankungen entwickelt, hat im dritten Abschluss seiner Serie-A-Finanzierungsrunde weitere 12 Mio. EUR eingesammelt. Damit summiert sich das Gesamtvolumen der Runde
